GlassScriptPhysician profile
Jake P Bostrom
NPI 1295886125
$4,027.86
in general payments reported to CMS, 2019-2025
25 companies · $606 in 2025
The $606 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $327 · 2021: $798 · 2022: $273 · 2023: $903 · 2024: $648 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,156.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,077.63 | 2019-2025 | Clareon, Argos, Rocklatan |
| Abbvie INC. | $363.78 | 2023-2025 | Combigan, Vuity, Restasis Multidose |
| Mallinckrodt Hospital Products INC. | $225.08 | 2020-2025 | Acthar |
| Sight Sciences, INC. | $223.43 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Allergan, INC. | $170.35 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $128.91 | 2019-2024 | |
| Amgen INC. | $118.00 | 2024-2025 | Tepezza |
| Omeros Corporation | $103.62 | 2019-2021 | |
| Ivantis, INC | $81.46 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $61.65 | 2019 | |
| Rxsight INC | $61.26 | 2024-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Glaukos Corporation | $60.52 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $50.25 | 2023-2024 | Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $42.15 | 2019-2021 | |
| Harrow Eye, LLC | $39.10 | 2025 | Vevye |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $35.06 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $31.00 | 2025 | Xdemvy |
| Ocular Therapeutix, INC. | $29.03 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $23.03 | 2019 | |
| New World Medical,INC. | $22.58 | 2023 | |
| Carl Zeiss Meditec USA, INC. | $19.33 | 2022 | |
| Merz Pharmaceuticals, LLC | $18.25 | 2025 | Xeomin |
| Shire North American Group INC | $15.01 | 2019 | |
| Oyster Point Pharma, INC. | $14.14 | 2024 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $13.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jake Bostrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.